Clinical Trial Update: The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing dose-dense AC-T versus TP as adjuvant therapy for triple-negative breast cancer with homologous recombination repair deficiency i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• AC-T (doxorubicin, cyclophosphamide, paclitaxel)
• TP

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: UNKNOWN